Simtra BioPharma Solutions has opened its new manufacturing facility in Bloomington, Indiana, following an investment of more than $250 million. Simtra BioPharma’s New Bloomington Plant, known as Building H, will expand the company’s capacity to manufacture sterile injectable medicines, including products filled into prefilled syringes and vials.
The company officially inaugurated the 153,000-square-foot facility on November 9, 2026. Indiana Governor Mike Braun, Bloomington Mayor Kerry Thomson, company executives, employees, and local officials attended the opening ceremony. The Simtra Bloomington facility launch marks a significant step in strengthening its manufacturing network and meeting the changing needs of pharmaceutical customers.
Simtra BioPharma’s New Bloomington Plant Expands Injectable Manufacturing
Simtra BioPharma’s Building H introduces new manufacturing capabilities for prefilled syringes, vials, and lyophilization. These technologies will allow Simtra to support a wider range of sterile injectable medicines.
Simtra BioPharma’s New Bloomington plant includes three important capabilities:
- Prefilled syringes: Ready-to-use syringes containing a measured dose of medication.
- Vial manufacturing: Filling injectable medicines into small, sealed containers for storage and administration.
- Lyophilization: A freeze-drying process that removes moisture from medicines to improve their stability and shelf life.
These capabilities strengthen Simtra BioPharma new manufacturing plant operations and support the production of increasingly complex injectable medicines.
CEO Franco Negron said, “Building H represents much more than additional manufacturing capacity. It is an important milestone in the growth strategy we are executing across Simtra.”
He added that the company is investing in the technology and infrastructure needed to support pharmaceutical customers and bring essential injectable medicines to patients worldwide.
Bloomington Manufacturing Expected to Increase Jobs
The Simtra BioPharma Solutions manufacturing expansion is also expected to create hundreds of jobs in Indiana.
According to reports, Building H currently employs approximately 100 people. Patrick J. Adams, Simtra’s vice president of expansion operations, expects the facility’s workforce to reach around 300 employees by the end of 2027. This could bring Simtra BioPharma’s total Bloomington workforce close to 2,000.
The company offers employment opportunities across production, engineering, maintenance, and supply chain operations.
The investment in new Bloomington manufacturing facility also supports the Indiana biosciences industry by strengthening the state’s pharmaceutical manufacturing infrastructure and creating additional employment opportunities.
Simtra BioPharma’s New Bloomington Plant Boosts Global Operations
The new Bloomington manufacturing facility forms part of Simtra’s broader international growth strategy. The company is also investing more than $125 million to expand manufacturing capacity at its Simtra Germany facility in Halle.
Additionally, Simtra has committed more than $150 million to its Bloomington Park Campus. Across its US and European operations, the company plans to increase its total filling lines from 11 to 18 by 2027.
Chief Operating Officer Ray Guidotti explained that customers need manufacturing partners capable of planning for future demand.
Simtra BioPharma’s Building H provides additional production capacity in the United States, while the company’s European investments strengthen its international manufacturing network. Together, these projects aim to offer pharmaceutical customers greater flexibility in where and how they manufacture medicines.
Simtra Plans Another Major Bloomington Manufacturing Expansion
Simtra is already preparing another manufacturing expansion at a former Cook Group property on North Curry Pike in Bloomington. The company purchased the 65-acre property for $45 million in 2025 and is investing hundreds of millions of dollars to renovate the site and install manufacturing equipment.
Unlike Building H, the new development will introduce highly potent manufacturing capabilities. These processes require specialized containment systems to prevent powerful pharmaceutical compounds from escaping into the surrounding environment.
Simtra expects the site to begin operations in a little over a year. The company believes the campus could eventually become three times the size of Building H.
